| Symbol | RTGN |
|---|---|
| Name | RETINALGENIX TECHNOLOGIES INC |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | 94954 United States CA 1450 North McDowell Boulevard Suite 150 |
| Telephone | (415) 578-9583 |
| Fax | — |
| — | |
| Website | https://retinalgenix.com/ |
| Incorporation | US |
| Incorporated On | 2017 |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | Liebman Goldberg & Hymowitz LLP;EisnerAmper LLP; |
| Audit Status | AUDITED |
| Reporting Status | U.S. Reporting: SEC Reporting |
| CIK | 0001836295 |
| Description | RetinalGenix Technologies Inc. is an innovative ophthalmic research and development company seeking to revolutionize early disease detection and improve patient outcomes across multiple disease areas. Its proprietary High-Resolution Retinal Imaging and DNA/RNA/GPS™ Pharmaco-Genetic Mapping™ technologies are designed to help prevent blindness by detecting initial physiological changes that could indicate future ocular and systemic diseases affecting neurodegenerative, cardiovascular, vascular and metabolic systems, as well as diabetic conditions, Alzheimer’s disease and Parkinson’s disease. RetinalGenix is also developing therapeutic drugs for dry age-related macular degeneration (dry AMD) and Alzheimer’s disease/dementia. By integrating genetic screening, advanced imaging, and therapeutic development, RetinalGenix is positioned to become a leader in precision medicine. Additional info from OTC: |
📋 Steven Bayern for Bayern Capital LLC (Shareholder) plans to sell 182K shares of RetinalGenix Technologies Inc. (at $3.20 each, total $584K) Filed: Feb 25, 2026 | ID: 007996
Read moreRetinalGenix Technologies Agrees To Hire M. Cory Zwerling as CFO, Interim COO
Read moreRetinalGenix Technologies Contracts with Seer Bio to Explore Early Detection of Neurodegenerative, Systemic, and Retinal Diseases
Read moreRetinalGenix Technologies and RGEN Clinical Genotyping Laboratory Announce Strategic Collaboration to Advance Early Detection of Neurodegenerative, Systemic, and Retinal Diseases
Read moreRetinalGenix Technologies Advances Home and Remote Monitoring Patent Portfolio, Positioning for the Future of Ocular and Systemic Disease Care
Read moreNew Form NT 10-Q - RetinalGenix Technologies Inc. Filed: 2025-08-14 AccNo: 0001641172-25-023652 Size: 38 KB
Read more📋 Steven Bayern for Bayern Capital LLC (Shareholder) plans to sell 100K shares of RetinalGenix Technologies Inc. (at $3.54 each, total $354K) Filed: Aug 12, 2025 | ID: 023217
Read moreNew Form EFFECT - RetinalGenix Technologies Inc. Filed: 2025-06-27 AccNo: 9999999995-25-002047 Size: 1 KB
Read moreNew Form EFFECT - RetinalGenix Technologies Inc. Filed: 2025-06-27 AccNo: 9999999995-25-002048 Size: 1 KB
Read moreRetinalGenix Technologies Contracts with LabCorp to Support DNA/GPS Platform for Advanced Genetic and Retinal Health Screening
Read more